• 11 Jun 2018

Morning Song

BCA Marketplace, 163 | Summit Therapeutics, 21.5

    • N+1 Singer Team

    • 8 pages

Stock Image


 
Stock Image


BCA Marketplace (BCA LN) Apax offer underplays the growth potential and forecast upside risk | Summit Therapeutics (SUMM LN) Second N. gonorrhoeae target identified |

Sign up to access

Get access to our full offering from over 30 providers

Get access to our full offering from over 30 providers


Get Started
Already a member? Log in here

More Content

More Content

Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole progress

Companies: Summit Therapeutics

Summit Therapeutics - Initial trials of ridinilazole

Companies: Summit Therapeutics

Summit Therapeutics CEO says anti microbial resistance will be as big a problem as climate change

Companies: Summit Therapeutics

N+1 Singer - Morning Song 28-06-2016

Companies: NTG BAR BCA

Q2 results: Ridinilazole Phase III on track

Companies: Summit Therapeutics

Copyright © 2019 Research Tree | All Rights Reserved. | Terms of Service and Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Tools licensed and contents implemented and optimized by Digital Look Ltd.

DigitalLook |Web Financial Group

©1999-2013 – Digital Look Ltd. A Web Financial Group Company All rights reserved. Legal notice.

Top